Aligos Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Stockholders’ Equity
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balance as of December 31, 2021 | 42,690,229 | $4 | $487,347 | $(303,072) | $452 | $184,731 |
| Issuance of common stock upon exercise of stock options | 12,896 | - | 20 | - | - | 20 |
| Issuance of common stock related to ESPP purchase | 219,855 | - | 205 | - | - | 205 |
| Stock-based compensation expense related to employee stock awards | - | - | 13,540 | - | - | 13,540 |
| Stock-based compensation expense related to employee stock purchases | - | - | 1,292 | - | - | 1,292 |
| Vesting of early exercised common stock options | - | - | 209 | - | - | 209 |
| Other comprehensive loss | - | - | - | - | (51) | (51) |
| Net loss | - | - | - | (96,046) | - | (96,046) |
| Balance as of December 31, 2022 | 42,922,980 | $4 | $502,613 | $(399,118) | $401 | $103,900 |
| Issuance of common stock upon exercise of stock options | 17,109 | - | 23 | - | - | 23 |
| Issuance of common stock related to ESPP purchase | 727,551 | - | 551 | - | - | 551 |
| Issuance of common stock in connection with PIPE offering, net of offering costs | 31,429,266 | 3 | 18,641 | - | - | 18,644 |
| Issuance of pre-funded warrants in connection with PIPE offering, net of offering costs | - | - | 48,079 | - | - | 48,079 |
| Costs related to the PIPE offering | - | - | (4,300) | - | - | (4,300) |
| Stock-based compensation expense related to employee stock awards | - | - | 11,799 | - | - | 11,799 |
| Stock-based compensation expense related to employee stock purchases | - | - | 853 | - | - | 853 |
| Vesting of early exercised common stock options | - | - | 66 | - | - | 66 |
| Other comprehensive income | - | - | - | - | 144 | 144 |
| Net loss | - | - | - | (87,679) | - | (87,679) |
| Balance as of December 31, 2023 | 75,096,906 | 7 | 578,325 | (486,797) | 545 | 92,080 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.